Minnesota-based Tendyne Holdings raises $25 million in a Series C funding round supporting its transcatheter mitral valve implantation systems for treating mitral regurgitation.
Medtech startup Tendyne Holdings landed $25 million in Series C funding, planning on using the new cash for further research & development of its transcatheter mitral valve technology.
The 4-year-old company's device provides minimally invasive treatment of mitral regurgitation. Tendyne is working on engineering an implantation system that would allow physicians to re-position or retrieve the valve even after full deployment.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1gccWZa
Cap comentari:
Publica un comentari a l'entrada